Status:
NOT_YET_RECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Injury, Spinal Cord
Eligibility:
All Genders
18+ years
Brief Summary
SCI is a devastating neurological disorder for which there are not yet restorative therapies. Thus, there is a need to explore new therapeutic strategies to treat SCI patients. To this end an appropri...
Detailed Description
SCI is a devastating neurological disorder for which there are not yet restorative therapies. Thus, there is a need to explore new therapeutic strategies to treat SCI patients. To this end an appropri...
Eligibility Criteria
Inclusion
- ASIA impairment scale grade A, B, or C upon admission;
- neurological level of injury between C1-L1;
- patient older than 18 years;
- ability to collect a valid, reliable baseline neurologic examination within 24h of injury.
Exclusion
- Concomitant TBI;
- major axial or appendicular trauma;
- in case of sedation or intoxication making unreliable the neurological examination.
Key Trial Info
Start Date :
August 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06537427
Start Date
August 30 2024
End Date
August 30 2026
Last Update
August 28 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.